Dr. Eric Jonasch

Dr. Eric Jonasch is a Professor of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, USA. He is internationally recognised as a world authority on kidney cancer, renal cell carcinoma, and von Hippel-Lindau disease, with over 20 years of specialised clinical and research experience.

Dr. Jonasch primarily specialises in kidney cancer, including clear cell renal cell carcinoma, metastatic RCC, and recurrent or treatment-resistant kidney cancer. He also specialises in von Hippel-Lindau disease and VHL-associated tumours, including renal tumours, CNS hemangioblastomas, and pancreatic neuroendocrine tumours. He treats selected bladder and advanced genitourinary cancers as part of his broader GU oncology practice.

Belzutifan is a first-in-class oral HIF-2α inhibitor approved for selected patients with VHL-associated tumours and advanced renal cell carcinoma after prior systemic therapy. Dr. Jonasch has been closely involved in the clinical research that led to its development and approval, including pivotal trial work evaluating its efficacy in VHL-associated renal tumours, CNS hemangioblastomas, and pancreatic neuroendocrine tumours. His work in this area has directly changed the treatment landscape for patients with VHL disease and advanced RCC.

International patients may seek consultation at MD Anderson Cancer Center, subject to appointment availability and case eligibility. CancerFax can help international patients prepare their medical records, pathology reports, imaging, and prior treatment history for expert review and guide them through the second-opinion and consultation process.

A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging files, prior treatment records, molecular or NGS reports, and a summary of current symptoms and performance status. The CancerFax team will review the case, prepare a structured medical summary, and support coordination with the MD Anderson Genitourinary Oncology team. The final consultation format and availability depend on the doctor's schedule and the hospital's case acceptance process.

For a kidney cancer or VHL disease consultation, patients should prepare: the diagnosis and pathology report, immunohistochemistry results, CT or MRI reports and imaging files in DICOM format, surgical notes if a nephrectomy was performed, details of all prior treatments including immunotherapy, targeted therapy, and chemotherapy, genetic testing results especially for VHL or hereditary cancer syndromes, molecular profiling or NGS reports if available, and recent blood tests and organ function reports.